4-(4-Methylpiperidin-1-yl)-N7-(beta-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine

ID: ALA5174504

PubChem CID: 168273567

Max Phase: Preclinical

Molecular Formula: C17H24N4O4

Molecular Weight: 348.40

Names and Identifiers

Canonical SMILES:  CC1CCN(c2ncnc3c2ccn3[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)CC1

Standard InChI:  InChI=1S/C17H24N4O4/c1-10-2-5-20(6-3-10)15-11-4-7-21(16(11)19-9-18-15)17-14(24)13(23)12(8-22)25-17/h4,7,9-10,12-14,17,22-24H,2-3,5-6,8H2,1H3/t12-,13-,14-,17-/m1/s1

Standard InChI Key:  BKDQJTAZWZBLGN-VMUDFCTBSA-N

Molfile:  

 
     RDKit          2D

 25 28  0  0  0  0  0  0  0  0999 V2000
   -3.5659   -0.5299    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1534   -1.2444    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3283   -1.2444    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8435   -0.5770    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0589   -0.8319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0589   -1.6569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8435   -1.9117    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0985   -2.6964    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3915   -2.1418    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3915   -0.3470    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.3929   -0.6020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7285   -1.3556    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5490   -1.4418    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0339   -0.7744    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.6983   -0.0208    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1831    0.6465    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.8475    1.4004    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3325    2.0680    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1532    1.9817    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4889    1.2279    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0038    0.5602    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5659    2.6964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8778    0.0653    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3929    0.7328    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3915    0.4778    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  2  1  1
  4  3  1  0
  4  5  1  0
  6  5  1  0
  7  6  1  0
  3  7  1  0
  7  8  1  6
  6  9  1  6
  5 10  1  1
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 17 16  1  0
 18 17  1  0
 19 18  1  0
 20 19  1  0
 21 20  1  0
 16 21  1  0
 19 22  1  0
 15 23  1  0
 11 23  2  0
 23 24  1  0
 24 25  2  0
 25 10  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5174504

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 348.40

Molecular Weight (Monoisotopic): 348.1798

AlogP: 0.28

#Rotatable Bonds: 3

Polar Surface Area: 103.87

Molecular Species: NEUTRAL

HBA: 8

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.46

CX Basic pKa: 6.13

CX LogP: 0.80

CX LogD: 0.77

Aromatic Rings: 2

Heavy Atoms: 25

QED Weighted: 0.73

Np Likeness Score: 0.23

References

1. Lin C, Jaén Batista DDG, Mazzeti AL, Donola Girão R, de Oliveira GM, Karalic I, Hulpia F, Soeiro MNC, Maes L, Caljon G, Van Calenbergh S..  (2022)  N⁶-modification of 7-Deazapurine nucleoside analogues as Anti-Trypanosoma cruzi and anti-Leishmania agents: Structure-activity relationship exploration and In vivo evaluation.,  231  [PMID:35144125] [10.1016/j.ejmech.2022.114165]

Source

Source(1):

• Scientific Literature